Wu Qianyun, Shao Hongda, Zhai Wei, Huang Gang, Liu Jianjun, Calais Jeremie, Wei Weijun
Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Nat Rev Urol. 2024 Nov 14. doi: 10.1038/s41585-024-00962-z.
The clinical diagnosis of renal cell carcinoma (RCC) is constantly evolving. Diagnostic imaging of RCC relying on enhanced computed tomography (CT) and magnetic resonance imaging (MRI) is commonly used for renal mass characterization and assessment of tumour thrombosis, whereas pathology is the gold standard for establishing diagnosis. However, molecular imaging is rapidly improving the clinical management of RCC, particularly clear-cell RCC. Molecular imaging aids in the non-invasive visualization and characterization of specific biomarkers such as carbonic anhydrase IX and CD70 within the tumours, which help to assess tumour heterogeneity and status. Target-specific molecular imaging of RCCs will substantially improve the diagnostic landscape of RCC and will further facilitate clinical decision-making regarding initial staging and re-staging, monitoring of recurrence and metastasis, patient stratification and selection, and the prediction and evaluation of treatment responses.
肾细胞癌（RCC）的临床诊断在不断发展。依靠增强计算机断层扫描（CT）和磁共振成像（MRI）的RCC诊断成像通常用于肾肿块的特征描述和肿瘤血栓形成的评估，而病理学是确诊的金标准。然而，分子成像正在迅速改善RCC的临床管理，尤其是透明细胞RCC。分子成像有助于在肿瘤内对特定生物标志物（如碳酸酐酶IX和CD70）进行非侵入性可视化和特征描述，这有助于评估肿瘤的异质性和状态。RCC的靶向特异性分子成像将极大地改善RCC的诊断前景，并将进一步促进关于初始分期和再分期、复发和转移监测、患者分层和选择以及治疗反应预测和评估的临床决策。
